肝硬化对各种肝病肝细胞癌发生的实际影响 - 荟萃分析评价

StephenW

Cancer Med. 2019 Feb 21. doi: 10.1002/cam4.1998. [Epub ahead of print]
Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment.
Tarao K1, Nozaki A2, Ikeda T3, Sato A4, Komatsu H5, Komatsu T6, Taguri M7, Tanaka K8.
Author information

1
    Tarao's Gastroenterological Clinic, Yokohama, Japan.
2
    Gastroenterological Center, Medical Center, Yokohama City University, Yokohama, Japan.
3
    Gastroenterology Department, Yokosuka General Hospital Uwamachi, Yokosuka, Japan.
4
    Division of Gastroenterology, Department of Internal Medicine, St. Marianna University, Yokohama City Seibu Hospital, Yokohama, Japan.
5
    Department of Gastroenterology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
6
    Department Clinical Research, National Hospital Organization, Yokohama Medical Center, Yokohama, Japan.
7
    Department of Data Science, Yokohama City University, Yokohama, Japan.
8
    Hatano Red Cross Hospital, Kanagawa, Japan.

Abstract
BACKGROUND:

It is well known that the incidence of developing hepatocelluler carcinoma (HCC) is increased in liver cirrhosis of different etiologies. However, comparison of HCC incidence in various liver diseases has not yet been estimated. We surveyed this comparison.
METHODS:

The PubMed database was examined (1989-2017) for studies published in English language regarding the prospective follow-up results for the development of HCC in various liver diseases. A meta-analysis was performed for each liver disease.
RESULTS:

The annual incidence (%) of HCC in the non-cirrhotic stage and cirrhotic stage, and the ratio of HCC incidence in the cirrhotic stage/non-cirrhotic stage were as follows. (a) hepatitis B virus liver disease: 0.37%→3.23% (8.73-fold), (b) hepatitis C virus liver diseases: 0.68%→4.81% (7.07-fold), (c) primary biliary cholangitis (0.26%→1.79%, 6.88-fold), (d) autoimmune hepatitis (0.19%→0.53%, 2.79-fold), and (e) NASH (0.03%→1.35%, 45.00-fold). Regarding primary hemochromatosis and alcoholic liver diseases, only follow-up studies in the cirrhotic stage were presented, 1.20% and 2.06%, respectively.
CONCLUSIONS:

When the liver diseases advance to cirrhosis, the incidence of HCC is markedly increased. The development of HCC must be closely monitored by ultrasonography, magnetic resonance imaging, and computed tomography, irrespective of the different kinds of liver diseases.

© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
KEYWORDS:

hepatocellular carcinoma; liver cirrhosis; liver diseases; meta-analysis; risk of HCC

PMID:
    30791221
DOI:
    10.1002/cam4.1998

StephenW

癌症医学。 2019年2月21日.doi：10.1002 / cam4.1998。 [印刷前的电子版]
肝硬化对各种肝病肝细胞癌发生的实际影响 - 荟萃分析评价。
Tarao K1，Nozaki A2，Ikeda T3，Sato A4，Komatsu H5，Komatsu T6，Taguri M7，Tanaka K8。
作者信息

1
    Tarao's Gastroenterological Clinic，Yokohama，Japan。
2
    横滨市立大学医学中心消化内科，日本横滨。
3
    日本横须贺市横须贺市横须贺总医院消化内科。
4
    日本横滨市横滨市西武医院圣玛丽安娜大学内科，消化内科。
五
    日本横滨市横滨市民医院消化内科。
6
    日本横滨市横滨医疗中心国立医院组织部门临床研究。
7
    横滨市立大学数据科学系，日本横滨。
8
    日本神奈川县波多野红十字会医院。

抽象
背景：

众所周知，在不同病因的肝硬化中发展的肝细胞癌（HCC）的发病率增加。然而，尚未估计HCC在各种肝病中的发病率的比较。我们调查了这个比较。
方法：

PubMed数据库（1989-2017）用于研究以英语发表的关于HCC在各种肝病中发展的前瞻性随访结果的研究。对每种肝脏疾病进行荟萃分析。
结果：

HCC在非肝硬化阶段和肝硬化阶段的年发病率（％），以及肝硬化阶段/非肝硬化阶段HCC发病率的比例如下。 （a）乙型肝炎病毒肝病：0.37％→3.23％（8.73倍），（b）丙型肝炎病毒肝病：0.68％→4.81％（7.07倍），（c）原发性胆汁性胆管炎（0.26％→ 1.79％，6.88倍），（d）自身免疫性肝炎（0.19％→0.53％，2.79倍），和（e）NASH（0.03％→1.35％，45.00倍）。关于原发性血色素沉着症和酒精性肝病，仅在肝硬化阶段进行了随访研究，分别为1.20％和2.06％。
结论：

当肝病进展为肝硬化时，HCC的发病率显着增加。必须通过超声波检查，磁共振成像和计算机断层扫描密切监测HCC的发展，而不论肝脏疾病的种类如何。

©2019作者。癌症医学由John Wiley＆Sons Ltd.出版。
关键词：

肝细胞癌;肝硬化;肝病;荟萃分析; HCC的风险

结论：
    30791221
DOI：
    10.1002 / cam4.1998